Antiretroviral treatment considerations in Latino patients

AIDS Patient Care and STDs

Volumn 19, Issue 6, 2005, Pages 366-374

  Campo, Rafael E ^a,c   Alvarez, Daniel ^b   Santos, Guillermo ^c   Latorre, Juan ^c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c University of Medicine and Dentistry of New Jersey ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; STAVUDINE; TENOFOVIR;

CAUCASIAN; DEMOGRAPHY; ECONOMIC ASPECT; ETHNIC DIFFERENCE; HEALTH CARE ACCESS; HEALTH CARE MANAGEMENT; HEALTH EDUCATION; HETEROSEXUALITY; HISPANIC; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; REVIEW; SIDE EFFECT; SOCIOECONOMICS; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ATTITUDE TO HEALTH; CULTURAL CHARACTERISTICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HISPANIC AMERICANS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 21844438959     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2005.19.366     Document Type: Review

References (36)

1. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. 2002;14:1-48. www.cdc.gov/hiv/stats/hasrlink.htm (Last accessed March 1, 2000).
2. Ramirez R, de la Cruz GP. The Hispanic Population in the United States: March 2002, Current Population Reports, P20-545. Washington, D.C.: US Census Bureau.
3. Centers for Disease Control and Prevention. HIV/AIDS Surveillance by Race/Ethnicity. March 2003.
4. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. 2001;13:2:1-44.
5. Galanti GA. The Hispanic family and male-female relationships: An overview. J Transcult Nurs 2003;14: 180-185.
6. Hirsch JS, Higgins J, Bentley ME, Nathanson CA. The social constructions of sexuality: Marital infidelity and sexually transmitted disease-HIV risk in a Mexican migrant community. Am J Public Health 2002; 92:1227-1237.
7. Marin BV. HIV prevention in the Hispanic community: Sex, culture, and empowerment. J Transcult Nurs 2003;15:217-230.
8. Murphy DA, Johnston Roberts K, Hoffman D, Molina A, Lu MC. Barriers and successful strategies to antiretroviral adherence among HIV-infected monolingual Spanish-speaking patients. AIDS Care 2003;15: 217-230.
9. US Census Bureau. Census 2000 Supplementary Survey. www.census.gov (Last accessed March 1, 2005).
10. Van Servellen G, Brown JS, Lombardi E, Herrera G. Health literacy in low-income Latino men and women receiving antiretroviral therapy in community-based treatment centers. AIDS Patient Care STDs 2003;17: 283-298.
11. van Servellen G, Carpio F, Lopez M, et al. Program to enhance health literacy and treatment adherence in low-income HIV-infected Latino men and women. AIDS Patient Care STDs 2003;17:581-594.
12. Essien EJ, Meshack AF, Ross MW. Misperceptions about HIV transmission among heterosexual African-American and Latino men and women. J Natl Med Assoc 2002;94:304-312.
13. Ebrahim SH, Anderson JE, Weidle P, Purcell DW. Race/ethnic disparities in HIV testing and knowledge about treatment for HIV/AIDS: United States, 2001. AIDS Patient Care STDs 2004;18:27-33.
14. Pulerwitz J, Amaro H, Dejong W, Gortmaker SL, Rudd R. Relationship power, condom use and HIV risk among women in the USA. AIDS Care 2002;14: 789-800.
15. Morales LS, Cunningham WE, Galvan FH, Andersen RM, Nakazono TT, Shapiro MF. Sociodemographic differences in access to care among Hispanic patients who are HIV infected in the United States. Am J Public Health 2004;94:1119-1121.
16. Mills RJ, Bhandari S. Health insurance coverage in the United States: 2002, Consumer Income, Current Population Reports, P60-223. Washington, D.C.: US Census Bureau.
17. Morin SF, Sengupta S, Cozen M, et al. Responding to racial and ethnic disparities in use of HIV drugs: Analysis of state policies. Public Health Rep 2002; 117:263-272.
18. Hodges JC, Khoshnood K, Stevens D. Delay in medical care after HIV diagnosis in men of color who have sex with men. Program and abstracts of the XIV International AIDS Conference, July 7-12, 2002, Barcelona, Spain. Abstract MoPeB3269.
19. Paris RM, Brown AE, Milazzo M, et al. Effectiveness of antiretroviral therapy among race/ethnic groups with similar access to healthcare: Results from the tri-service study of human immunodeficiency virus disease in US military beneficiaries [Abstract TuPeC4702]. Program and Abstracts of the XIV International AIDS Conference. Barcelona, Spain: July 7-12, 2002.
20. Swindells S, Cobos DG, Lee N, et al. Racial/ethnic differences in CD4 T cell count and viral load at presentation for medical care and in followup after HIV-1 infection. AIDS 2002;16:1832-1834.
21. Wood E, Montaner JS, Alfonso V, et al. Treatment access and HIV/AIDS deaths in the era of "chronic" infection, in a setting that delivers antiretrovirals and AIDS care free of charge. [Abstract TuPeC4753] Program and Abstracts of the XIV International AIDS Conference. Barcelona, Spain: July 7-12, 2002.
22. Crystal S, Sambamoorthi U, Moynihan P, McSpiritt E. Predictors of persistent use of newer antiretroviral agents over time in a low-income US population with HIV/AIDS [Abstract WePeB5977]. Program and Abstracts of the XIV International AIDS Conference, Barcelona, Spain: July 7-12, 2002.
23. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
24. Bangsberg DR, Charlebois ED, Grant RM, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 2003;17:1925-1935.
25. Brun S, Kempf D, Bernstein B, et al. The pharmacologic barrier to resistance: Differential patterns of viral evolution in protease inhibitors naïve and experienced patients during viral load rebound on Kaletra (lopinavir/r) therapy [Abstract 7]. Program and Abstracts of the 8th European Conference on Clinical Aspects and Treatment of HIV Infection. Athens, Greece: October 2001.
26. Campo RE, Lichtenberger PN, Rosa I, et al. Differences in the frequency of resistance to antiretroviral drug classes among human immunodeficiency virus type 1 clinical isolates. Clin Microbiol 2003;41:3376-3378.
27. King M, Bernstein B, Cernohous P, Moseley J, Bauer E, Sun E. Impact of baseline CD4 cell count and viral load on durability of virologic response through 96 weeks for lopinavir/ritonavir (LPV/r) and nelfinavir (NFV) in a phase III clinical trial [Abstract 470]. Program and Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington: February 24-28, 2002.
28. Kempf D, King M, Bauer E, et al. Comparative incidence and temporal accumulation of PI and NRTI resistance in HIV-infected subjects receiving lopinavir/ritonavir or nelfinavir as initial therapy [Abstract 600]. Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts: February 10-14, 2003.
29. Elston R, Macmanus S, Yates P, White S, Richards N. Lack of resistance to boosted 908 confirmed through 48 weeks of therapy in naïve subjects [Abstract 558]. Program and Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France: July 13-16, 2003.
30. King M, Brun S, Tschampa J, Moseley J, Kempf D. Relationship between adherence and the development of viral resistance in antiretroviral-naïve patients treated with lopinavir/ritonavir (LPV/r) or nelfinavir (NFV) [Abstract 798], Program and Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France: July 13-16, 2003.
31. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. AIDSinfo. nih.gov/guidelines (Last accessed March 1, 2005).
32. Tashima K, Staszewski S, Morales-Ramirez J, et al. 3-year durability of response with an efavirenz (EFV)-containing regimen: 144 week followup of study 006 [Abstract 224]. Program and Abstracts of the 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina: July 8-11, 2001.
33. Eron J, DaSilva B, King M, et al. Lopinavir/ritonavir in antiretroviral-naive HIV-infected patients: 5-year follow-up [Abstract H-844]. Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois: September 14-17, 2003.
34. Nieto-Cisneros L, Zala C, Fessel WJ, et al. Antiviral efficacy, metabolic changes and safety of atazanavir (ATV) versus lopinavir/ritonavir (LPV/RTV) in comparison with 2 NRTIs in patients who have experienced virologic failure with prior Pi-containing regimens: 24-week results from BM [Abstract 117]. Program and Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France: July 13-16, 2003.
35. DeJesus E, Grinsztejn B, Rodriguez C, et al. Efficacy and safety of atazanavir with ritonavir or saquinavir versus lopinavir/ritonavir in patients who have experienced virologic failure on multiple HAART regimens: 48-week results from BMS AI424-045 [Abstract 547]. Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, California: February 8-11, 2004.
36. DeJesus E, La Marca A, Sension M, Beltran C, Yeni P. The Context study: efficacy and safety of GW433908/RTV in PI-experienced subjects with virological failure (24 week results) [Abstract 178]. Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts: February 10-14, 2003.